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RESUMO 
 
Os carcinomas de células escamosas da cabeça e pescoço foram os sextos cancros mais 
comuns em Portugal em 2010. Uma detecção precoce, uma melhor estratégia 
terapêutica levaram a um aumento da sobrevivência e da qualidade de vida dos doentes. 
No entanto, o risco de desenvolver um segundo cancro primário permanece elevado 
nesta população, constituindo um importante factor de morbilidade. Aproximadamente 
um terço das mortes dos carcinomas da cabeça e pescoço são imputáveis aos segundos 
primários cancros. 
Um segundo cancro primário apesar de poder ser considerado uma recaída, é diferente 
de uma recorrência tumoral, pelo facto de não se originar a partir do tumor primário, 
apresentando um processo carcinogénico distinto que origina um novo tumor. A sua 
detecção precoce revela-se um factor fundamental para aumentar as hipóteses de um 
tratamento com intuito curativo. Para tal, é fundamental um melhor conhecimento dos 
mecanismos que levam ao aparecimento destes segundos tumores, quais as localizações 
mais frequentes e qual a probabilidade e tempo necessário para ocorrerem. 
O objectivo deste estudo foi comparar os diversos relatos na literatura científica, sobre a 
realidade da distribuição dos segundos cancros primários e a sua frequência após um 
tratamento inicial para um carcinoma da cabeça e pescoço. O conhecimento desta 
realidade será de grande importância para o médico dentista, permitindo uma adequada 
gestão dos doentes com cancro oral. 
 
A revisão bibliográfica foi realizada a partir das bases PubMed, B-on, Cancer Network, 
Science Direct e repositório institucional da Universidade Fernando Pessoa. 
 
Palavras chave: “segundo cancro primário”, “cabeça e pescoço”, “carcinoma de 
células escamosas”, “cancro oral”.  
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ABSTRACT 
Head and Neck squamous cell carcinoma (HNSCC) was the sixth most common cancer 
in Portugal in 2010. Earlier detection, better therapeutic management has led to an 
increase survival in patients' lifespan and quality of life. However, the risk of 
developing second primary malignancy remains elevated in this population and is still 
an important morbidity factor. Approximately one-third of HNSCC deaths are 
attributable to second primary cancers. 
A second primary cancer may be considered a relapse, but differs from tumour 
recurrence, by the fact that it doesn’t originate from the primary tumor and presents its 
own carcinogenic process that will generate a new tumor. Early detection is a 
fundamental factor to increase the hypotheses of a treatment with a curative objective. 
For these reasons it is fundamental to have a better knowledge of the appearance 
mechanisms of secondary tumours, their most frequent locations and how likely and 
how long they can occur. The purpose of this study is to compare the different relations 
in the scientific literature and articles, to analyse the reality of the distribution of second 
primary cancers and their frequency after initial treatment for a head and neck 
carcinoma. Knowledge of this reality will be important for the dentist, allowing 
adequate management of patients with oral cancer.  
 
A bibliographic review was carried from PubMed, B-on, Cancer Network, Science 
Direct and the Fernando Pessoa University institutional repository.  
 
Key words: “second primary malignancy”; “head and neck”; “squamous cell 
carcinoma”; “oral cancer”. 
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I- INTRODUCTION 
 
Head and neck cancers affect the various aerodigestive structures which are the oral 
cavity (OC), the thyroid and salivary glands, the pharynx, the larynx, the nasal cavity 
and its sinuses. They derive predominantly from the epithelium: more than 90% of 
theses cancers are Squamous Cell Carcinomas (Reid et al., 2018).  
 
Incidence of head and neck squamous cell carcinoma (HNSCC) in the United-States is 
between 11.3-15%, for the period of 2011-2015, according to Noone et al. (2018), based 
a 30 year follow up database from the Surveillance, Epidemiology, and End Results 
Program (SEER).  
It is the sixth most frequent cancer in the world in 2008 and also in Portugal (Jemal et 
al., 2011) (RORENO, 2016).  
 
Second primary cancer (SPC) is considered as a relapse but unlike tumour recurrence, 
SPC does not originate from the first tumour but has its own carcinogenic process, 
leading to a new tumour (Gleber-Netto et al., 2015). The development of SPC in cancer 
survivors remains one of the most life-threatening sequelae (Wood et al., 2012). 
According to Farhadieh et al. (2009) SPC have a reported incidence of 5–30% 
following successful treatment of the index tumour. 
 
According to Curtis and colleagues (Curtis et al., 2006), survivors of a first cancer have 
a 14% higher risk of developing SPC than the general population (considering all first 
and second cancer sites, based on the SEER database program). According to the same 
authors, the number of diagnoses of SPC continues to increase, reaching 16% of cancers 
reported in the United States. 
 
After an oral squamous cell carcinoma (OSCC), the incidences of SPC can vary from 
10% to 18.4% (Ko et al., 2016).  
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An early detection of SPC increases the chances of successful salvage therapy (Agrawal 
et al., 2004). A better understanding of the resurgence mechanisms, the probability, the 
place and the time required before the occurrence of a SPC, seems to be of growing 
interest. 
 
This monography, based on a bibliographic review and focused on the development of 
SPC in patients who have developed HNSCC, aims to provide an overview of the 
reality of SPC in this subpopulation. Dentists are therefore on the front line and have an 
essential role to play in the management and early diagnosis of possible new 
malignancies in this at-risk population. 
 
I.1.   Materials and methods 
 
For the purpose of this dissertation a bibliographic review was conducted on the theme 
Second Primary Cancer/ Head and Neck Cancer through the consultation of data from 
PubMed, B-on, Cancer Network, Science Direct and from the institutional repository of 
the Fernando Pessoa University. 
 
The Key words used to conduct this research were: second Primary Malignancy, head 
and neck, squamous cell carcinoma, oral cancer.  
 
A total of 63 references found, including books, scientific articles and journals. The 
inclusion criteria were the language (articles written in English, Portuguese and French), 
the possession of complete articles and the types of index tumour (head and neck 
squamous cell carcinoma). The research period goes from 1990 to 2018, without date 
limitation for a will to transcribe the evolution of conception and reality of SPC. The 
exclusion criteria were about articles on first non-squamous cell carcinoma such as 
Hodkigian lymphomas or lymphoepithelial carcinomas. In accordance with the 
relevance and framework of the subject, it has been selected 55 references in this 
dissertation.  
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II- DEVELOPMENT 
 
1.   Second primary cancer definition  
SPC is a term used to describe a tumour that develops independently from a first 
tumour. There are two principal set of rules to define SPC. The North American used in 
the SEER program cancer registries and the rules developed by the International 
Agency for Research on Cancer (IARC) used internationally, mainly for reporting. 
(Coyte, 2014) 
 
Concerning the IARC coding rules, they aim is to suggest a simple set of rules for 
international comparative purposes. These rules state the following for the squamous 
cell carcinomas (Muir, 1991): The recognition of the existence of two or more primary 
cancers does not depend on time. A primary cancer is one which originates in a primary 
site or tissue and is thus neither an extension, a recurrence nor a metastasis.   
The North American classification considers histology, site, laterality and time since 
initial diagnosis (Coyte, 2014). The diagnosis of a SPC must be done considering 
several elements, which are the standard criteria based on the Warren and Gates SPC’s 
definition (cit. in Farhadieh et al., 2009):  
1- The new tumour is separated from at least 2 cm from the index tumour or was 
diagnosed >5 years apart. 
2- Its reported as a malignant histology (in both the index and secondary tumours). 
3- The index tumour should be completely excised as assessed by histological 
examination. 
4- The possibility of distant metastasis should be histologically excluded. 
It should be noted that there are 2 possible types of SPC, according to Moertel (cit. in 
Vaamonde et al., 2003): synchronous or metachronous. Synchronous for a cancer 
diagnosed within 6 months, metachronous for a cancer diagnosed after more than 6 
months. 
Second primary malignancy after curative treatment of oral squamous cell carcinoma 
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2.   Definition’s limitation 
There is a certain limit in the application of these criteria. Indeed, the malignancy of a 
lesion can be determined by histopathological examination, but other criteria are 
problematics and are source of debate. 
Concerning differentiation between synchronous and metachronous, reference authors 
such as Hong et al. (1990) uses the 6 months criteria. However, it should be stressed 
that the IARC and Europeans studies are using a two month criteria. At last a one-
month period could also be used (Liao et al., 2006).  
 
Relating to the distance between the tumours, the studies are divergent. Certain studies 
like Hong et al. (1990) uses the 2cm criteria. Other studies use a greater distance (3 cm 
in Tabor et al., 2002), or the contrary, shorter distance (1.5 cm in Scholes et al., 1998). 
Some authors also point out, between the two close sites, the possible presence of 
malignant extensions which can collide, below the apparent healthy mucosa. This 
further complicates diagnosis and differentiation between a potential OSCC 
synchronous or metachronous and a SPC (Sarode, 2010). 
 
Many studies have been conducted using a molecular approach. For exemple, Gutiérrez 
et al. (2011) compared the genetic profiles of index tumour, SPC and recurrences. They 
highlighted the existence of discrepancies between genetic classification and clinical 
classification, showing that the clinicopathological criteria weren’t always a relevant 
differentiation tool.  
 
3.   Second primary cancer risk factors  
The aim is to provide an understanding of the major groups and factors that explain the 
high rate of SPC in patients with HNSCC, not to realize an exhaustive list. In their 
study, Wood et al. (2012) classify the risks in function of: treatment related, syndromic, 
etiologic exposure. These factors can obviously be interrelated. The different risk 
factors developed in this study are exposed in Fig.1. 
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Fig1. Origin of the different risk factors in SPC occurrence. 
 
i.   Treatment related  
Concerning impact of radiotherapy (RT) on the SPC’s advent, Rusthoven et al. (2008) 
showed that RT reduced the risk of SPC in the larynx and pharynx and had no impact 
on the occurrence of SPC in the OC (positive for patients treated before 1988). 
However, some other studies have shown a possible increase of SPC after RT for an 
index tumour. For exemple Gao et al. (2002), found that RT for laryngeal index cancer 
increases the risk of developing a SPC by 10% and developing a SPC in the Head and 
Neck (HN) area by 26%. 
These two studies, based on the SEER database, provide two diametrically opposed 
points of view, but both of which are probable. In relation to treatments and more 
specifically to radiotherapy, there is no consensus. An explanation would be the 
interrelationship and inability to separate the different risk factors, (Farhadieh et al., 
2009). According to Seegobin et al. (2018) the different treatments: RT, chemotherapy 
and hormonal therapy, are associated to neoplastic development. However, this study 
shows that there is no significant difference in the SPC rates, after any of these 
treatments, or after any combination of these treatments. 
Some data highlight the fact that children and young adults are most vulnerable to the 
carcinogenic effects of radio-chemotherapy. However, there is no increase of a 
subsequent cancer risk, after a cancer therapy for older adults (Bhatia et al., 2005). 
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ii.   Genetic/Syndromic 
Concerning heredity, Brown et al. (2001) was among the first to suggest that it could 
exist family factors (genetic) about HNSCC risk. They insisted that studies on this 
subject include many biases particularly alcohol and tobacco consumption. It was also 
suggested that HNSCC patients with a family history of HNSCC have an increased risk 
of SPC (Bongers et al., 1996).  
According to Yokoyama and Omori (2002), the inactive forms of aldehyde 
dehydrogenase-2 present in certain populations (particularly in eastern Asia) are related 
to a higher risk of HNSCC, increasing with a stronger link with highly alcohol 
exposure, especially in some subsites like pharynx. 
 
There are many cancer syndromes, caused by mutations in tumour suppressor genes, 
oncogenes, and genes involved in angiogenesis. Although they are quite rare, it’s 
essential that general dental practitioner has knowledge about these oral potentially 
malignant disorders which can be crucial in the prognostic (Sarode et al. 2016). Here 
we’ll mention the Fanconi anaemia (FA) and the Li-Fraumeni Syndrome (LFS). 
According to Adelstein (2005), FA is caused by mutations in DNA repair genes which 
lead to a higher risk of developing multiple malignancies. A registry-based cohort study 
noticed that a clear majority of HNSCC patients with FA have no history of alcoholism 
or tobacco use. This allows to identify FA as a risk factor for HNSCC (Kutler et 
al.,2003). 
LFS is related to germline mutations of the p53 tumour suppressor gene. An equal and 
high prevalence of p53 mutations, is found in erythroplasia lesions and in leukoplasia 
lesions related to tobacco use (Quin et al. 1999) which are involved in OSCC genesis.  
 
iii.   Etiological exposure 
Tobacco consumption causes many cancers and is, strongly and scientifically associated 
with the appearance of primary cancers and SPC of the upper aerodigestive tract (OC, 
pharynx, larynx, esophagus) and lung (Shiels et al., 2014). Alcohol is also a strong oral 
carcinogenic factor and has a potential synergistic role of carcinogenesis with tobacco 
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consumption (Petti, 2008). According to Ernani (2015), separately or in association, 
they are the source of 75% of the HNSCC. 
 
Since 1984, HPV infection has been responsible for an increased incidence of 
oropharyngeal cancers in the United-States and paradoxically caused an increase in their 
survival (Chaturvedi et al., 2011). According to Neumann et al. (2016) it also seems that 
a first cancer caused by HPV is a risk factor for SPC, and his relapse will often occur in 
other frequent HPV-related areas. The incidence of SPC of the HN is lower in cancer-
related HPVs than in non-HPVs related cancers (Diaz et al., 2015). 
 
In certain regions of the world (Asia, Indian subcontinent) the consumption of betel nuts 
(often associated with chewing tobacco) is also an important factor in the 
carcinogenesis of the OC and the upper airways (Asthana et al., 2018). It has been 
proven that a diet rich in fruits and vegetables plays a protective role of HN cancer 
development. After the first HN cancer treatment, smoking and alcohol cessation 
incentives should be accompanied by nutritional advices (Falciglia et al., 2005).  
 
III- ASSOCIATION INDEX TUMOUR /SECOND PRIMARY CANCER  
 
1.   Localisation first primary cancer 
In 1994, Schwartz et al. realised a study with 851 patients who suffered a first head and 
neck cancer (FHN), diagnosed between 1978 and 1990. The objective was to study the 
distribution of the first primary cancer (FPC) and SPC. Patients underwent different 
forms of treatment: surgical, radiotherapy and chemotherapy. Of the 851 FHN (follow 
up period up to 169 months), 19% (162 cases) developed a SPC. The distribution of 
FHN and SPC is shown in Fig 2. 
The first four localisations of the FHN are larynx with 26.3% (224 cases), followed by 
tonsillae with 22.2% (189 cases), pyriform sinus with 19.4% (165 cases) and OC with 
15.2% (129 cases). It should be noted that anatomic sites of the oral cavity are 
considered separately in this study (oral cavity, mobile tongue and base of the tongue). 
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Their combination leads the OC to 32.1% (273 cases), that brings it in the first place of 
FHN localisation. 
 
 
Fig 2. FPC and SPC distribution based on a study of Schwartz et al., 1994. 
 
In their study, Jégu et al. (2013) realised a retrospective study using the french regional 
Bas-Rhin database covering the period from 1975 to 2006. They identified 6258 
patients with FHN (their follow-up time of 10 years). They found as the main FHN 
appearance site, the OC 35.5% (2223 cases), followed by hypopharynx 22.8% (1423 
cases), larynx 21.9% (1373 cases) and oropharynx 19.8% (1239 cases). Another study 
based on the SEER registry covering the period from 1975 to 2006, used 75.087 cases 
of diagnosed FHN (the median follow up was 69.1 months). They noticed in first 
importance the OC 48.1% (36.107 cases), followed by larynx 34.1% (25.624 cases), 
oropharynx 11.2% (8440 cases), and hypopharynx 6.5% (4916 cases) (Morris et al., 
2011b). 
In numerous studies, OC is the first site of FHN development, which is consistent with 
the literature (Vaamonde et al., 2003, Morris et al., 2011b, Jégu et al.,2013).  
 
Relating patients with a first oral cavity cancer (FOC), Liu et al. (2013) study was one 
of the few focusing on FOC and the different subsite of the OC. Out of a total of 72 
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patients with a first oral cavity cancer, they have found the following repartition: tongue 
43% (31 cases), buccal mucosa 39% (28 cases), gingiva 8% (6 cases), lip 7% (5 cases), 
floor of the mouth 1.5% (1 case), retromolar trigone 1.5% (1case). These results are 
presented in Fig.3.  
 
 
Fig 3. Localisation of FOC based on a study of Liu et al., 2013. 
 
2.   Synchronous/Metachronous  
Firstly, it should be noted that all the articles used in this section distinguish 
synchronous from metachronous using a 6-month criteria. 
 
Relating to patients with a first head and neck cancer, the preceding study of Schwartz 
et al. (1994), out of the 162 cases of SPC, found an appearance of 41% (66 cases) of 
synchronous and 59% (96 cases) of metachronous (Fig.4).  
Another study realised a clinical study on 636 patients with FHN (Vaamonde et al., 
2003). In total, 7.5% (48 cases) developed a SPC (the follow up period was up to 122 
months). They noticed 37.5% (18 cases) of synchronous and 62.5% (30 cases) of 
metachronous (Fig.4). 
Relating to patients with a first oral cavity cancer and SPC appearance, Van der Wall 
and De Bree (2010), reported a study from De Vries which included 210 patients with a 
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FOC. Among these patients 18% (38 cases) developed a SPC (during 8.4 years follow 
up period). These SPC were 10.5% (4 cases) synchronous and 89.5% (34 cases) 
metachronous (Fig.4). In another study by Cianfriglia et al. (1998) concerning 200 
patients with a FOC, 18% (36 cases) developed a SPC. Among these 36 SPC, 39.4% 
(13 cases) were synchronous and 60.6% (20 cases) were metachronous (Fig.4).  
It should be noted that, in the last study, (Cianfriglia et al., 1998) are included patients 
with FOC, but also patients with a FPC of the oropharynx. 
Relating other localisations of the FHN, Li et al. (2011) realised a study including 329 
patients with a first primary tongue cancer (FTC). He showed that 8.8% (29 cases) 
developed a SPC (the minimum follow up period was 36 months). In that study 6.9% (2 
cases) were reported as synchronous and 93.1% (27 cases) as metachronous (Fig.4). 
A retrospective study conducted by Hsu et al. (2008) on 538 patients with FTC and first 
primary larynx cancer (FLC), showed 14.3% (77 cases) of SPC incidence (follow up 
median period of 73 months). They found 10.4% (8 cases) of synchronous and 89.6% 
(69 cases) of metachronous (Fig.4). 
In a study about 181 patients with a second primary lung cancer consecutive to an FHN 
(FH&N/SLC in Fig.4), the synchronous proportion was 22.1% (40 cases) and 77.1% 
(141 cases) for metachronous (Griffioen et al., 2015).  
 
 
Fig 4. Repartition Synchronous/Metachronous in different studies. 
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3.   Localisation second primary cancer  
Regarding the localisation of SPC after a first head and neck cancer, Scwhartz et al. 
(1994) found 40.2% (65 cases) for the sum of all the HN subsites, 33.3% (54 cases) for 
oesophagus e 26.5 % (43cases) for lung. In their study, Vaamonde et al. (2003) found 
that second primary cancer of the head and neck was the most common (72.9%), 
followed by lung (14.6%) and oesophagus (8.3%) reminding that it is congruent with the 
literature.  
According to Morris et al. (2011b), based on the analyse of 75,087 cases of FHN, the 
SPC localisations most frequents were: OC 48.1% (36,107cases), larynx 34.1% (25,624 
cases), oropharynx 11.2% (8,440 cases) and hypopharynx 6.5% (4,916 cases). 
 
Concerning the SPC localisation after a first oral cavity cancer, Liu et al. (2013) found 
that 27.8% (20 patients among the 72 with a FOC) developed SPC. The main SPC 
localisation was in the oral cavity: 75% (15 cases). 
 
However, according with the literature, the crude incidence of SPC doesn’t reflect the 
excess risk of cancer due to the FHN. The standardized incidence ratio (SIR) is more 
accurate. SIR is the ratio of observed to expected SPC with an 95% of confidence 
interval (CI), it measures the relative risk (RR) of the event on an individual level and 
does not depend on the frequency of the event in the population (Morris et al., 2011a).  
The excess absolute risk (EAR) represents the absolute number of additional second 
cancers attributable to the index HNSCC. EAR is calculated as the excess (observed—
expected) number of second cancers in patients with an index HNSCC diagnosis, per 
10,000 person-years at risk (PYR). EAR measures the population impact (Morris et al., 
2011a).  
 
According to Jégu et al. (2013), after a first oral cancer, the SIR for all sites is 5.4 (95% 
CI, 5.0 to 5.9) with an EAR equal to 511, for the lung & bronchus, SIR equal to 9.8 
(95% CI, 8.3 to 11.6), EAR equal to 159.3. For the HN, SIR equal to 17.7 (95% CI, 15.2 
to 20.6), EAR equal to 201. And for oesophagus, SIR equal to 22.6 (95 CI, 17.6 to 
28.7), EAR equal to 82.9.  
Second primary malignancy after curative treatment of oral squamous cell carcinoma 
 
12 
 
After an FOC, according to these results, the risk to develop a cancer in the oesophagus 
is 22.6 time higher than in the normal population and the FOC is responsible for 201 
SPC cases per 10,000 PYR.    
 
In Morris et al. (2011b) study, based on the SEER registry database, showed that SPC 
risk differed significantly in function of FHN subsite. The SIR of a second solid tumour 
at any site was highest for patients with an index hypopharynx (3.5; 95% CI, 3.3 to 3.7), 
followed by oropharynx (3.0; 95% CI, 2.9 to 3.1), oral cavity (2.8; 95% CI, 2.7 to 2.9), 
and larynx (1.9; 95% CI, 1.9 to 2.0).  
 
In the Fig.5, (taken from Morris et al., 2011b) is exposed EAR of SPC in function of the 
first head and neck cancer site. It is observed that the EAR of second solid cancers per 
10,000 PYR was highest in patients with an index hypopharyngeal (307.1), and lowest 
for index larynx (147.8). After an FOC and a FPC of the oropharynx, the highest 
number of excess SPCs occurred in the HN. For larynx and hypopharynx primary 
cancers, the highest number of excess SPCs occurred in the lung (Fig. 5, Morris et al., 
2011b). 
 
 
Fig 5. Excess absolute risk of second primary malignancy (SPM), by site of index head and neck cancer: (A) index 
oral cavity, (B) index oropharynx, (C) index larynx, and (D) index hypopharynx cancer (adapted from Morris et al., 
2011 b). 
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4.   Incidence and survival 
According to Curtis et al. (2006) SPC diagnosis number is constantly increasing, 
reaching 16% of reported cancers in United-States, however this number is less 
important in Europe: 6.3% (Rosso et al., 2009). 
 
Based on the results of Jégu et al. (2013) (with a 10 year follow up period), 1336 
patients developed a SPC unlike the 284 expected, giving a SIR of 4.7 (95% CI, 4.4 to 
4.9). In this study and during this period, patients with a FHN have 4.7 times a risk to 
develop a cancer than the normal population.  
According to Morris et al. (2011a), SPC’s occurrence in patients treated for a FHN is 
estimated at 2–6% per year and in a continuous way among years.  
According to Vaamonde et al. (2003), more than 50% of the SPC were detected in a 
period of 1.5 years after the diagnosis of the FHN. 
After a first oral cancer treatment, in Liu et al. (2013) study, 80% (16 cases) of the SPC 
were diagnosed within 5 years. The incidence of SPT was 5% per year and was constant 
during the follow-up period of at least 7 years.  
 
The overall survival after diagnosis of SPC in the Vaamonde et al. (2003) study, is 
87.5% at 6 months, 68.7% at 1 year, 43.5% at 3 years, and 29% at 5 years. According to 
the same authors the survival rate associated with the SPC is poor, worse if it is in an 
advanced stage, located outside the HN area or if it is synchronous.  
 
IV- DISCUSSION 
 
Firstly, we could notice that there are few studies realised about the SPC after a FOC.  
The definition itself shows some limitations and there is obviously a lack of 
standardisation that difficult the comparison between studies. Different criteria are used, 
that could lead to misclassification (SEER in North America and IARC internationally 
and for reporting). The SEER classification includes a greater number of SPC than in 
the IARC classification (Coyte, 2014). 
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In some aspect, clinical classification seems less precise than the molecular 
classification.  
There is room for improvement, that would affect comparative studies, management and 
prognostication (Gleber-netto et al., 2015). The research about molecular background of 
field cancerization, such with the TP53 mutation could bring us new solutions (Morris 
et al., 2011a).  
However, this classification is not yet matured and doesn’t take the total precedence 
over the clinical classification (Gleber-Netto et al., 2015).  
 
The patients risk behaviours are frequently inter-related, that could bias the studies 
(Brown et al., 2001). 
It also be noted the important heterogeneity of the studies on this theme. The subsites of 
anatomic regions could be combine or considered separately, for exemple Schwartz et 
al. (1994), will distinguish the oral cavity from the mobile tongue and the base of the 
tongue unlike other studies which will regroup them into one site. Some studies like 
Cianfriglia et al. (1998) and Li et al. (2011) will consider three forms of SPC: 
simultaneous, synchronous and metachronous. Other studies have defined arbitrarily the 
FPC as the first tumour detected (Vaamonde et al., 2003).  
Limitations of the registries (time, treatment, risk factors) and the unequal follow up 
period remains also important difficulties for the comparison. Finally, Cianfriglia et al. 
(1998) reminds us the low power statistics of various small studies. 
 
Despite all these initial adverse factors, it can still be said that, according to many 
studies, the most frequent FHN location is the oral cavity and within the oral cavity, the 
tongue is most affected. 
Most of the time cancers are metachronous. After a FHN, SPC are located mostly in the 
HN area, then in the lungs and oesophagus.  
Approximately 75% of SPCs after an OSCC emerge in the oral cavity (Liu et al., 2013). 
According to Morris et al. (2011b), if the FPC is low in the upper aerogestive tract, the 
risk of developing a SPC will be higher in the lung and bronchus area. 
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The survival rate among the patients affected by a SPC remains low: 29% at 5 years. 
The prognosis is even worse if it is in an advanced stage, located outside the region of 
the head and neck or if it is synchronous (Vaamonde et al., 2003). 
 
There is a lack of evidence-based guidelines and a regular and long-term monitoring 
surveillance of SPC development is necessary to improve the survival rate (Liu et 
al.,2013). 
New studies should be conducted on the person at risk follow up, focusing on the 
preclinical detectable phase, timing and risk of a SPC. But also, by considering the cost 
of the follow up as well as the supportability for the patients (Brands et al., 2018) and 
the role of the dental practitioner. 
Dentist training in early detection of pre-cancerous lesions is important. An information 
work must also be conducted with patients, too many cancers are diagnosed at an 
advanced stage. The patient should no longer consult only when he has toothache, but 
maintain regular follow-up 
 
V- CONCLUSION 
Few reports have been made on reality of the SPC after a FHN and even less after a 
FOC.  
There are populational differences and as well specific history for each patient. On the 
one hand, efforts should be made to standardise the criteria of population registers in 
order to assess general trends and the emergence of potential new influences. On the 
other hand, at a more specific level, notably based on genetic research, new studies 
should be conducted to better adapt the treatment and the follow up to each patient and 
their history. 
The role of the dentist can be crucial in the early detection and in the quality of life after 
a FHN, and must be aware of the increment of this type of patients in their daily routine. 
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